Blood
Blood
5 years ago

Single-Agent Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia: A 5-Year Experience.

William Wierda, Jeff Sharman, Kristie Blum, Richard R Furman, John C Byrd, Amy J Johnson, Nyla A Heerema, Susan O'Brien, Danelle F James, Ying Luan, Weiquiang Zhao, Alvina D Chu, Jan A Burger, Jeffrey Jones, Ian W Flinn, Steven Coutre
We previously reported durable responses and manageable safety of ibrutinib from a 3-year follow-up of treatment-naive (TN) older patients (≥65 years) and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). We now report on long-term efficacy and safety with median follow-up of 5 years in this patient population with TN (N=31) and R/R (N=101) CLL/SLL. With the current 5-year follow-up, ibrutinib continues to yield a high overall response rate of 89%, with complete response rates increasing over time to 29% in TN and 10% in R/R patients. The median progression-free survival (PFS) was not reached in TN patients. The 5-year PFS rate was 92% in TN and 44% in R/R patients. Median PFS in R/R patients was 51 months and in those with del(11q), del(17p), and unmutated IGHV was 51, 26, and 43 months, respectively, demonstrating long-term efficacy of ibrutinib in some high-risk subgroups. Survival outcomes were less robust for R/R patients with del(17p) and those who received more prior therapies. The onset of grade ≥3 cytopenias, such as neutropenia, and thrombocytopenia, decreased over time. Treatment-limiting adverse events were more frequent during the first year compared with subsequent time periods. These results demonstrate sustained efficacy and acceptable tolerability of ibrutinib over extended time, providing the longest experience for Bruton's tyrosine kinase inhibitor treatment in patients with CLL/SLL. The trials were registered at www.clinicaltrials.gov as NCT01105247 and NCT01109069.

Publisher URL: http://doi.org/10.1182/blood-2017-10-810044

DOI: 10.1182/blood-2017-10-810044

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.